The type 2 diabetes additional trial regarding (kidney) renal complications.If this trial shows efficacy it will mean that Mesoblasts technology will be able to attack this disease on 2 fronts with one treatment or multiple treatments. Attacking the scource and the symptoms.People with advanced Kidney desease have to go on regular dialysis. So far with the diabetes trial we are 50% there with the first results showing efficacy, comparable to other treatments.Lets hope the second phase of the trial shows efficacy because it will be so benefical to the people that have Renal complications from type 2 Diabetes.Results should not be to far away!
Celgene, page-11
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.46 |
Change
0.065(4.66%) |
Mkt cap ! $1.667B | |||
| Open | High | Low | Value | Volume |
| $1.41 | $1.50 | $1.40 | $5.699M | 3.943M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 122380 | $1.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 11015 | 2 |
View Market Depth
| Last trade - 16.10pm 11/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |